Kendra Sweet

*Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA

About this speaker

Dr Sweet is a clinical investigator with a focus on AML and CML. She has opened 2 multi-center Phase II clinical trials for which she is the national PI. These 2 trials build on her previous work with ruxolitinib in combination with TKIs for treatment of chronic phase of chronic myeloid leukemia (CML). One trial is being run through the Southwest Oncology Group Leukemia Committee and the second will be with the J Khoury Cure CML Consortium. Dr. Sweet has also just opened a Phase I investigator initiated clinical trial in acute myeloid leukemia (AML) combining CPX-351 plus the FLT3-inhibitor gilteritinib. In addition to this, she has been the PI in a number of sponsored clinical trials in AML and BPDCN, and much of her work has led to abstract submissions and presentations at ASH, ASCO and the European School of Hematology Annual Meetings.


Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice | Satellite Symposium

25 September 2021, 04:00 PM
Giuseppe Saglio Kendra Sweet Ehab Atallah